Ticker
ADXN

Price
1.22
Stock movement up
+- (%)
Company name
Addex Therapeutics Ltd
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
7.70M
Ent value
-2.46M
Price/Sales
3.34
Price/Book
0.59
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-87.68%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

ADXN does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales3.34
Price to Book0.59
EV to Sales-1.06

FINANCIALS

Per share

Loading...
Per share data
Current share count6.31M
EPS (TTM)-2.93
FCF per share (TTM)-2.66

Income statement

Loading...
Income statement data
Revenue (TTM)2.31M
Gross profit (TTM)0.00
Operating income (TTM)-18.12M
Net income (TTM)-18.54M
EPS (TTM)-2.93
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-784.67%
Profit margin (TTM)-802.66%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash14.89M
Net receivables434.63K
Total current assets17.16M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets17.68M
Accounts payable1.42M
Short/Current long term debt412.87K
Total current liabilities3.97M
Total liabilities4.73M
Shareholder's equity12.96M
Net tangible assets12.96M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-16.78M
Capital expenditures (TTM)28.39K
Free cash flow (TTM)-16.81M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-143.08%
Return on Assets-104.83%
Return on Invested Capital-139.92%
Cash Return on Invested Capital-126.89%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.20
Daily high1.23
Daily low1.17
Daily Volume52K
All-time high24.19
1y analyst estimate-
Beta1.75
EPS (TTM)-2.93
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
ADXNS&P500
Current price drop from All-time high-94.96%-12.18%
Highest price drop-96.21%-56.47%
Date of highest drop20 Jul 20229 Mar 2009
Avg drop from high-60.64%-11.38%
Avg time to new high196 days12 days
Max time to new high420 days1805 days
COMPANY DETAILS
ADXN (Addex Therapeutics Ltd) company logo
Marketcap
7.70M
Marketcap category
Small-cap
Description
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot"Marie"Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Employees
26
Investor relations
-
SEC filings
CEO
Timothy Dyer
Country
USA
City
Geneva
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Geneva, Switzerland, September 20, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, anno...
September 20, 2022
CHF8.8M ($9.3M) of cash and cash equivalents at June 30, 2022CHF4.6M equity financing in July extends cash runway into Q2 2023Janssen led ADX71149 Phase 2 study in epilepsy expected to report data in ...
August 18, 2022
Addex to Receive CHF850,000 ($900,000) of Additional Funding; Addex’s Reserved Indications Expanded to include Chronic Cough Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 15, ...
August 15, 2022
Geneva, Switzerland, August 12, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today a...
August 12, 2022
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 26, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modul...
July 26, 2022
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modul...
July 22, 2022
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 21, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulati...
July 21, 2022
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 21, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulati...
July 21, 2022
COVID-19 related challenges negatively impacted patient recruitment Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 17, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a ...
June 17, 2022
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 27, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulatio...
May 27, 2022
Next page